Role of Breast MR Imaging for Predicting Malignancy of Histologically Borderline Lesions Diagnosed at Core Needle Biopsy: Prospective Evaluation

Role of Breast MR Imaging for Predicting Malignancy of Histologically Borderline Lesions Diagnosed at Core Needle Biopsy: Prospective Evaluation
Federica Pediconi, Simona Padula, Valeria Dominelli, MariaLaura Luciani, Marianna Telesca, Valeria Casali, Miles A. Kirchin, Roberto Passariello, and Carlo Catalano
Radiology 2010; 257 653-661

Link to Journal

Correct identification of nonmalignant lesions at MR imaging could direct the patient toward imaging follow-up rather than surgical excision, thereby reducing both patient anxiety and costs related to the surgical procedure as well as avoiding surgical scarring--which potentially could alter the interpretation of subsequent imaging studies

Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy

Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy
Sonia P. Li, N. Jane Taylor, Andreas Makris, Mei-Lin W. Ah-See, Mark J. Beresford, J. James Stirling, James A. d'Arcy, David J. Collins, and Anwar R. Padhani
Radiology 2010; 257 643-652

Link to Journal



Intrinsic susceptibility-weighted MR imaging has the ability to provide information about blood volume in patients with primary breast cancer; it may also provide a means with which to evaluate changes in tumor oxygenation in response to chemotherapy

Can Preoperative Axillary US Help Exclude N2 and N3 Metastatic Breast Cancer?

Can Preoperative Axillary US Help Exclude N2 and N3 Metastatic Breast Cancer?
Colleen H. Neal, Caroline P. Daly, Alexis V. Nees, and Mark A. Helvie
Radiology 2010; 257 335-341

Link to Journal

Axillary US is a valuable modality for evaluating the preoperative status of the axilla and provides a noninvasive means with which to accurately exclude advanced axillary metastatic disease for 96% of patients with invasive ductal carcinoma